In 422 treatment-naïve Chinese adults with HIV-1, efavirenz 400 mg was non-inferior to 600 mg (both with lamivudine and tenofovir) for viral suppression at week 72: 86.5% vs 84.1%. Serious non-rash adverse events were more frequent with 600 mg.
RCTn = 422
Hang et al. Efavirenz 400 vs 600 mg combined with lamivudine and tenofovir in treatment-naïve HIV-infected patients in China: A randomized, multi-centered, controlled trial